SearcharxivSearch

arXiv · 2311.11046

Classification of Major Depressive Disorder Using Vertex-Wise Brain Sulcal Depth, Curvature, and Thickness with a Deep and a Shallow Learning Model

Roberto Goya-Maldonado·Tracy Erwin-Grabner·Ling-Li Zeng·Christopher R. K. Ching·Andre Aleman·Alyssa R. Amod·Zeynep Basgoze·Francesco Benedetti·Bianca Besteher·Katharina Brosch·Robin Bülow·Romain Colle·Colm G. Connolly·Emmanuelle Corruble·Baptiste Couvy-Duchesne·Kathryn Cullen·Udo Dannlowski·Christopher G. Davey·Annemiek Dols·Jan Ernsting·Jennifer W. Evans·Lukas Fisch·Paola Fuentes-Claramonte·Ali Saffet Gonul·Ian H. Gotlib·Hans J. Grabe·Nynke A. Groenewold·Dominik Grotegerd·Tim Hahn·J. Paul Hamilton·Laura K. M. Han·Ben J. Harrison·Tiffany C. Ho·Neda Jahanshad·Alec J. Jamieson·Andriana Karuk·Tilo Kircher·Bonnie Klimes-Dougan·Sheri-Michelle Koopowitz·Thomas Lancaster·Ramona Leenings·Meng Li·David E. J. Linden·Frank P. MacMaster·David M. A. Mehler·Susanne Meinert·Elisa Melloni·Bryon A. Mueller·Benson Mwangi·Igor Nenadić·Amar Ojha·Yasumasa Okamoto·Mardien L. Oudega·Brenda W. J. H. Penninx·Sara Poletti·Edith Pomarol-Clotet·Maria J. Portella·Elena Pozzi·Joaquim Radua·Elena Rodríguez-Cano·Matthew D. Sacchet·Raymond Salvador·Anouk Schrantee·Kang Sim·Jair C. Soares·Aleix Solanes·Dan J. Stein·Frederike Stein·Aleks Stolicyn·Sophia I. Thomopoulos·Yara J. Toenders·Aslihan Uyar-Demir·Eduard Vieta·Yolanda Vives-Gilabert·Henry Völzke·Martin Walter·Heather C. Whalley·Sarah Whittle·Nils Winter·Katharina Wittfeld·Margaret J. Wright·Mon-Ju Wu·Tony T. Yang·Carlos Zarate·Dick J. Veltman·Lianne Schmaal·Paul M. Thompson

Abstract

Major depressive disorder (MDD) is a complex psychiatric disorder that affects the lives of hundreds of millions of individuals around the globe. Even today, researchers debate if morphological alterations in the brain are linked to MDD, likely due to the heterogeneity of this disorder. The application of deep learning tools to neuroimaging data, capable of capturing complex non-linear patterns, has the potential to provide diagnostic and predictive biomarkers for MDD. However, previous attempts to demarcate MDD patients and healthy controls (HC) based on segmented cortical features via linear machine learning approaches have reported low accuracies. Here, we used globally representative data from the ENIGMA-MDD working group containing 7,012 participants from 30 sites (N=2,772 MDD and N=4,240 HC), which allows a comprehensive analysis with generalizable results. Based on the hypothesis that integration of vertex-wise cortical features can improve classification performance, we evaluated the classification of a DenseNet and a Support Vector Machine (SVM), with the expectation that the former would outperform the latter. We found that both classifiers exhibited close to chance performance (balanced accuracy DenseNet: 51%; SVM: 53%), when estimated on unseen sites. Slightly higher classification performance (balanced accuracy DenseNet: 58%; SVM: 55%) was found when the cross-validation folds contained subjects from all sites, indicating site effect. In conclusion, the integration of vertex-wise morphometric features and the use of the non-linear classifier did not lead to the differentiability between MDD and HC. Our results support the notion that MDD classification on this combination of such features and classifiers is unfeasible. Perhaps more sophisticated integration of multimodal information may lead to a higher performance in this diagnostic task.

Explore related subjects

Keep this discovery

BibTeXRIS

Roberto Goya-Maldonado, Tracy Erwin-Grabner, Ling-Li Zeng, Christopher R. K. Ching, Andre Aleman, Alyssa R. Amod, Zeynep Basgoze, Francesco Benedetti, Bianca Besteher, Katharina Brosch, Robin Bülow, Romain Colle, Colm G. Connolly, Emmanuelle Corruble, Baptiste Couvy-Duchesne, Kathryn Cullen, Udo Dannlowski, Christopher G. Davey, Annemiek Dols, Jan Ernsting, Jennifer W. Evans, Lukas Fisch, Paola Fuentes-Claramonte, Ali Saffet Gonul, Ian H. Gotlib, Hans J. Grabe, Nynke A. Groenewold, Dominik Grotegerd, Tim Hahn, J. Paul Hamilton, Laura K. M. Han, Ben J. Harrison, Tiffany C. Ho, Neda Jahanshad, Alec J. Jamieson, Andriana Karuk, Tilo Kircher, Bonnie Klimes-Dougan, Sheri-Michelle Koopowitz, Thomas Lancaster, Ramona Leenings, Meng Li, David E. J. Linden, Frank P. MacMaster, David M. A. Mehler, Susanne Meinert, Elisa Melloni, Bryon A. Mueller, Benson Mwangi, Igor Nenadić, Amar Ojha, Yasumasa Okamoto, Mardien L. Oudega, Brenda W. J. H. Penninx, Sara Poletti, Edith Pomarol-Clotet, Maria J. Portella, Elena Pozzi, Joaquim Radua, Elena Rodríguez-Cano, Matthew D. Sacchet, Raymond Salvador, Anouk Schrantee, Kang Sim, Jair C. Soares, Aleix Solanes, Dan J. Stein, Frederike Stein, Aleks Stolicyn, Sophia I. Thomopoulos, Yara J. Toenders, Aslihan Uyar-Demir, Eduard Vieta, Yolanda Vives-Gilabert, Henry Völzke, Martin Walter, Heather C. Whalley, Sarah Whittle, Nils Winter, Katharina Wittfeld, Margaret J. Wright, Mon-Ju Wu, Tony T. Yang, Carlos Zarate, Dick J. Veltman, Lianne Schmaal, Paul M. Thompson. 2023-11-18. Classification of Major Depressive Disorder Using Vertex-Wise Brain Sulcal Depth, Curvature, and Thickness with a Deep and a Shallow Learning Model. https://arxiv.org/abs/2311.11046

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

Biology-in-the-loop: Amortized Adaptive Hit Discovery in CRISPR Screens

Many biological discovery problems require experiments to be selected sequentially under constrained budgets. CRISPR screening is a prominent example, as exhaustive perturbation testing is often infeasible and candidate perturbations must instead be prioritized over multiple experimental rounds. Despite the importance of this problem, existing benchmarks for adaptive hit discovery remain limited in scale and diversity. Here, we introduce AssayBench-Loop, a large-scale benchmark for adaptive hit discovery comprising 1,389 CRISPR screens across five phenotype categories. Beyond enabling systematic evaluation, its scale makes it possible to learn acquisition strategies across historical experiments. Building on this resource, we introduce AssayLoop, a sequential experimental design framework combining AssayFormer, a transformer-based amortized acquisition policy trained across historical screens to adapt from experimental feedback, with LLM-derived biological priors through an adaptive handoff. In this view, completed experiments become training data for learning how accumulated evidence should guide what to test next, while LLMs provide prior biological knowledge to seed the search. We further introduce AssayLLM, showing that the same principle can be extended directly to an LLM through task-specific post-training. On temporally held-out screens, AssayLoop achieves a 5.67-fold enrichment over random selection and recovers 27.7% of hits after assaying approximately 5% of the candidate library, outperforming existing adaptive-design methods and standalone LLMs, and AssayFormer alone. Performance improves with increasing historical training data and transfers to phenotype categories excluded from training. These results demonstrate the value of learning acquisition policies across historical experiments and combining them with broad biological priors for efficient adaptive hit discovery.

q-bio.QM

Multi-Task Bacterial Colony Detection and Classification Using YOLOv8 with Edge Optimization for Resource-Constrained Deployment

Manual counting and classification of bacterial colonies are critical yet labor-intensive tasks in microbiology, prone to human error particularly on densely populated plates. This work proposes a multi-task deep learning framework trained on the Annotated Germs for Automated Recognition (AGAR) dataset (18,000 images; 9,202 training / 3,067 testing) to automate Colony Forming Unit (CFU) enumeration and species classification. A custom multi-task CNN employing global regression served as the baseline, but demonstrated limited performance in clustered colony environments due to the absence of spatial localization. To address this, a YOLOv8 object detection architecture was adopted with high-resolution 1024x1024 inputs, enabling instance-level colony detection and label assignment. The model achieved a classification accuracy of 98.13% and a counting accuracy of 98.27% (within a 10-colony margin), demonstrating strong predictive capability. To bridge the gap between model performance and practical deployability, the trained model was optimized through unstructured and structured pruning, ONNX conversion, and reduced-precision inference (FP32, FP16, INT8). On a Raspberry Pi 4B, ONNX FP32 and FP16 variants offered the best balance between inference speed (~6.4s) and accuracy (MAE ~2.20). Unstructured pruning preserved predictive accuracy (MAE ~2.01) without runtime gains, while structured pruning resulted in significant accuracy degradation (MAE ~6.3), revealing the sensitivity of instance-level colony detection to architectural compression. These findings provide practical guidance for selecting optimization strategies in resource-constrained laboratory deployments.

q-bio.QM

ADMET-EvO: a self-evolving scientific agent for sustained research across heterogeneous tasks

Scientific agents can move beyond automated model building by using accumulated evidence to revise both their questions and experimental strategies. The challenge is sustaining this adaptation across heterogeneous tasks without overfitting decisions to internal validation. Absorption, distribution, metabolism, excretion and toxicity (ADMET) prediction provides a demanding setting across diverse assays, datasets and chemical domains. We therefore developed ADMET-EvO, an evidence-gated agent that formalizes endpoints, generates falsifiable hypotheses and tests interventions across data, feature and model axes. It carries supported, rejected and inconclusive outcomes forward to guide each new cycle. Across the 22-task Therapeutics Data Commons (TDC) ADMET benchmark, ADMET-EvO achieved the highest task-normalized score of 96.77. Evidence-guided selection reduced cumulative fitting time by 72.2% within a predefined non-inferiority margin. It also formalized 43 toxicity-related tasks and constructed endpoint-specific predictors. Together, these results show how ADMET-EvO can accumulate evidence, revise its strategy and expand its research scope over time.

q-bio.QM